Henry Schein Shares Rise on Strong Q2 Results and Raised 2026 Guidance

Key Facts

1Henry Schein reported a 6.7% revenue increase to $3.46B in the second quarter.

2Management raised 2026 adjusted EPS guidance to a range of $5.29–$5.39.

In a move reflecting strong operational performance within the healthcare supplies sector, Henry Schein reported robust second-quarter financial results that led to share price outperformance against the S&P 500. According to reports, the company achieved a 6.7% revenue increase, reaching $3.46 billion during the quarter. This growth was driven by positive momentum across all business segments alongside improved net income and cash flow.

Following these solid results, management raised its full-year 2026 guidance, now projecting adjusted earnings per share to fall within a range of $5.29 to $5.39. This upward revision underscores management's confidence in sustained growth expectations for the remainder of the fiscal year, based on the latest analyst data.

Regarding market performance, HSIC shares stood at $84.84 (at close September 18, 2026), having reached a day high of $85.96. With no immediate sector-specific catalysts in the upcoming economic calendar, investors will be watching if the stock maintains support near the $84.41 level, which represented the low during the most recent trading session.